The socioeconomic burden of SLE
- PMID: 19506585
- DOI: 10.1038/nrrheum.2009.106
The socioeconomic burden of SLE
Abstract
Systemic lupus erythematosus (SLE) is a chronic, relapsing-remitting, multisystemic autoimmune inflammatory disorder that predominantly affects women of childbearing age. Much has been written about the clinical course and long-term damage associated with SLE, as well as the reduced life expectancy of patients with this condition. In addition, studies have emphasized the socioeconomic and psychosocial impact of SLE, although the monetary cost of caring for patients with the disorder has only been evaluated in a modest number of studies and a restricted number of countries. SLE has a negative impact on quality of life and is associated with high health-care costs and significant productivity loss. Factors associated with increased cost of SLE include long disease duration, high disease activity and damage, poor physical and mental health, and high education and employment levels. Similarly, high disease activity and damage, poor physical health, certain disease manifestations, as well as poor family and social support are associated with poor health-related quality of life outcomes. SLE incurs a great burden on both the patient and society. Long-term prospective studies should be encouraged to monitor the costs and psychosocial impact of this condition, and to better understand the factors that are associated with poor outcomes.
Similar articles
-
The economic burden of systemic lupus erythematosus.Best Pract Res Clin Rheumatol. 2012 Oct;26(5):695-704. doi: 10.1016/j.berh.2012.08.006. Best Pract Res Clin Rheumatol. 2012. PMID: 23218432 Review.
-
The socioeconomic burden of systemic lupus erythematosus: state-of-the-art and prospects.Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):53-69. doi: 10.1586/erp.11.92. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 22280197 Review.
-
Health-related quality of life in patients with systemic lupus erythematosus: a Spanish study based on patient reports.Clin Rheumatol. 2019 Jul;38(7):1857-1864. doi: 10.1007/s10067-019-04485-6. Epub 2019 Feb 28. Clin Rheumatol. 2019. PMID: 30820696
-
Characterization of the patterns of care, access, and direct cost of systemic lupus erythematosus in Brazil: findings from the Macunaíma study.Adv Rheumatol. 2024 Apr 19;64(1):30. doi: 10.1186/s42358-024-00369-9. Adv Rheumatol. 2024. PMID: 38641825 Review.
-
Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.J Med Econ. 2020 Jan;23(1):1-9. doi: 10.1080/13696998.2019.1678170. Epub 2019 Oct 21. J Med Econ. 2020. PMID: 31589081
Cited by
-
Prevalence and burden of pediatric-onset systemic lupus erythematosus.Nat Rev Rheumatol. 2010 Sep;6(9):538-46. doi: 10.1038/nrrheum.2010.121. Epub 2010 Aug 3. Nat Rev Rheumatol. 2010. PMID: 20683438 Review.
-
Identifying Barriers to Enrollment in Patient Pregnancy Registries: Building Evidence Through Crowdsourcing.JMIR Form Res. 2022 May 25;6(5):e30573. doi: 10.2196/30573. JMIR Form Res. 2022. PMID: 35612888 Free PMC article.
-
Autoantibody Profiling in Lupus Patients using Synthetic Nucleic Acids.Sci Rep. 2018 Apr 3;8(1):5554. doi: 10.1038/s41598-018-23910-5. Sci Rep. 2018. PMID: 29615791 Free PMC article.
-
Understanding Contributors of Resilience in Youth With Childhood-Onset Systemic Lupus Erythematosus Through a Socioecological Lens: A Mixed-Methods Study.Arthritis Care Res (Hoboken). 2025 Sep;77(9):1112-1124. doi: 10.1002/acr.25550. Epub 2025 Jun 10. Arthritis Care Res (Hoboken). 2025. PMID: 40223659 Free PMC article.
-
Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol.Lupus Sci Med. 2024 Jul 11;11(2):e001144. doi: 10.1136/lupus-2024-001144. Lupus Sci Med. 2024. PMID: 38991834 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical